TNSN06314A1 - Sulfonamides destines au traitement de troubles neurodegeneratifs - Google Patents
Sulfonamides destines au traitement de troubles neurodegeneratifsInfo
- Publication number
- TNSN06314A1 TNSN06314A1 TNP2006000314A TNSN06314A TNSN06314A1 TN SN06314 A1 TNSN06314 A1 TN SN06314A1 TN P2006000314 A TNP2006000314 A TN P2006000314A TN SN06314 A TNSN06314 A TN SN06314A TN SN06314 A1 TNSN06314 A1 TN SN06314A1
- Authority
- TN
- Tunisia
- Prior art keywords
- des
- formule
- composés
- troubles
- sulfonamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des composés de formule (I), dans laquelle R1, R2, R3, m et n répondent aux définitions mentionnées. Les composés de formule (I) ont une activité d'inhibition de la production de peptide A β. La présente invention concerne également des compositions pharmaceutiques et des méthodes pour le traitement de troubles et de maladies, par exemple de troubles neurodégénératifs et/ou neurologiques, par exemple la maladie d'Alzheimer, chez un mammifère, comprenant des composés de formule (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55866004P | 2004-04-01 | 2004-04-01 | |
PCT/IB2005/000796 WO2005095334A1 (fr) | 2004-04-01 | 2005-03-21 | Composes sulfonamides utilises dans le traitement des troubles neurodegeneratifs |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN06314A1 true TNSN06314A1 (fr) | 2007-12-03 |
Family
ID=34962303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2006000314A TNSN06314A1 (fr) | 2004-04-01 | 2006-09-29 | Sulfonamides destines au traitement de troubles neurodegeneratifs |
Country Status (28)
Country | Link |
---|---|
US (2) | US7163942B2 (fr) |
EP (1) | EP1747195A1 (fr) |
JP (2) | JP2007530660A (fr) |
KR (1) | KR20060130705A (fr) |
CN (1) | CN1938266A (fr) |
AP (1) | AP2006003729A0 (fr) |
AR (1) | AR048348A1 (fr) |
AU (1) | AU2005227749A1 (fr) |
BR (1) | BRPI0509477A (fr) |
CA (1) | CA2562114A1 (fr) |
CR (1) | CR8669A (fr) |
DO (1) | DOP2005000049A (fr) |
EA (1) | EA200601607A1 (fr) |
EC (1) | ECSP066888A (fr) |
GT (1) | GT200500070A (fr) |
IL (1) | IL177955A0 (fr) |
MA (1) | MA28493B1 (fr) |
MX (1) | MXPA06011348A (fr) |
MY (1) | MY136718A (fr) |
NL (1) | NL1028664C2 (fr) |
NO (1) | NO20064989L (fr) |
PE (1) | PE20060147A1 (fr) |
SV (1) | SV2006002073A (fr) |
TN (1) | TNSN06314A1 (fr) |
TW (1) | TW200602297A (fr) |
UY (1) | UY28825A1 (fr) |
WO (1) | WO2005095334A1 (fr) |
ZA (1) | ZA200607213B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
BRPI0509069B8 (pt) * | 2004-03-23 | 2021-05-25 | Pfizer Prod Inc | compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos |
RS20080139A (en) * | 2005-09-22 | 2009-05-06 | Pfizer Products Inc., | Imidazole coumpounds for the treatment of neurological disorders |
WO2008107335A1 (fr) * | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides comme antagonistes de l'orexine |
CN102088855A (zh) * | 2008-05-08 | 2011-06-08 | 百时美施贵宝公司 | 2-芳基甘氨酰胺衍生物 |
US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
WO2012162249A1 (fr) * | 2011-05-20 | 2012-11-29 | Benjamin Wolozin | Identification de composés qui dispersent des inclusions de tdp-43 |
WO2013026021A2 (fr) * | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka comme cible pour l'inhibition du clivage d'app et/ou la progression de la maladie d'alzheimer |
CN107722012B (zh) | 2016-08-11 | 2020-05-29 | 斯福瑞(南通)制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS484784U (fr) * | 1971-06-16 | 1973-01-19 | ||
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5491170A (en) * | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
EP0967201A1 (fr) | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Compositions pharmaceutiques contenant des sulphonamides comme inhibiteurs des métalloprotéinases matricielles |
AU2002346724B2 (en) | 2001-12-14 | 2009-04-30 | Exelixis, Inc. | Human ADAM-10 inhibitors |
ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
-
2005
- 2005-03-11 US US11/078,739 patent/US7163942B2/en not_active Expired - Fee Related
- 2005-03-21 JP JP2007505656A patent/JP2007530660A/ja active Pending
- 2005-03-21 KR KR1020067020447A patent/KR20060130705A/ko not_active Application Discontinuation
- 2005-03-21 EA EA200601607A patent/EA200601607A1/ru unknown
- 2005-03-21 AP AP2006003729A patent/AP2006003729A0/xx unknown
- 2005-03-21 CN CNA2005800106397A patent/CN1938266A/zh active Pending
- 2005-03-21 BR BRPI0509477-1A patent/BRPI0509477A/pt not_active IP Right Cessation
- 2005-03-21 AU AU2005227749A patent/AU2005227749A1/en not_active Abandoned
- 2005-03-21 EP EP05708793A patent/EP1747195A1/fr not_active Withdrawn
- 2005-03-21 MX MXPA06011348A patent/MXPA06011348A/es unknown
- 2005-03-21 WO PCT/IB2005/000796 patent/WO2005095334A1/fr active Application Filing
- 2005-03-21 CA CA002562114A patent/CA2562114A1/fr not_active Abandoned
- 2005-03-29 PE PE2005000354A patent/PE20060147A1/es not_active Application Discontinuation
- 2005-03-29 DO DO2005000049A patent/DOP2005000049A/es unknown
- 2005-03-29 GT GT200500070A patent/GT200500070A/es unknown
- 2005-03-29 UY UY28825A patent/UY28825A1/es not_active Application Discontinuation
- 2005-03-30 MY MYPI20051435A patent/MY136718A/en unknown
- 2005-03-30 AR ARP050101227A patent/AR048348A1/es unknown
- 2005-03-31 NL NL1028664A patent/NL1028664C2/nl not_active IP Right Cessation
- 2005-03-31 TW TW094110386A patent/TW200602297A/zh unknown
- 2005-04-01 SV SV2005002073A patent/SV2006002073A/es not_active Application Discontinuation
-
2006
- 2006-08-29 ZA ZA200607213A patent/ZA200607213B/xx unknown
- 2006-09-07 IL IL177955A patent/IL177955A0/en unknown
- 2006-09-27 EC EC2006006888A patent/ECSP066888A/es unknown
- 2006-09-29 TN TNP2006000314A patent/TNSN06314A1/fr unknown
- 2006-09-29 MA MA29352A patent/MA28493B1/fr unknown
- 2006-10-02 CR CR8669A patent/CR8669A/es not_active Application Discontinuation
- 2006-10-06 US US11/539,219 patent/US7345095B2/en not_active Expired - Fee Related
- 2006-10-31 NO NO20064989A patent/NO20064989L/no not_active Application Discontinuation
-
2008
- 2008-02-19 JP JP2008037819A patent/JP2008189673A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP066888A (es) | 2006-11-24 |
AR048348A1 (es) | 2006-04-19 |
BRPI0509477A (pt) | 2007-09-11 |
JP2008189673A (ja) | 2008-08-21 |
KR20060130705A (ko) | 2006-12-19 |
JP2007530660A (ja) | 2007-11-01 |
US7163942B2 (en) | 2007-01-16 |
US20050222254A1 (en) | 2005-10-06 |
NL1028664C2 (nl) | 2006-03-22 |
WO2005095334A1 (fr) | 2005-10-13 |
US7345095B2 (en) | 2008-03-18 |
AU2005227749A1 (en) | 2005-10-13 |
IL177955A0 (en) | 2006-12-31 |
EP1747195A1 (fr) | 2007-01-31 |
MA28493B1 (fr) | 2007-03-01 |
AP2006003729A0 (en) | 2006-10-31 |
PE20060147A1 (es) | 2006-03-08 |
US20070129349A1 (en) | 2007-06-07 |
GT200500070A (es) | 2005-10-31 |
CR8669A (es) | 2006-11-01 |
NO20064989L (no) | 2007-01-02 |
MXPA06011348A (es) | 2006-12-15 |
SV2006002073A (es) | 2006-05-09 |
MY136718A (en) | 2008-11-28 |
UY28825A1 (es) | 2005-10-31 |
ZA200607213B (en) | 2008-04-30 |
NL1028664A1 (nl) | 2005-10-05 |
TW200602297A (en) | 2006-01-16 |
CN1938266A (zh) | 2007-03-28 |
CA2562114A1 (fr) | 2005-10-13 |
DOP2005000049A (es) | 2005-12-15 |
EA200601607A1 (ru) | 2007-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN06314A1 (fr) | Sulfonamides destines au traitement de troubles neurodegeneratifs | |
TNSN06300A1 (fr) | Derives d'imidazole pour le traitement de troubles neurodegeneratifs | |
TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
TNSN06200A1 (fr) | Derives de quinoleine nouveaux | |
TNSN05249A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
MA27997A1 (fr) | Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
MA27132A1 (fr) | Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues | |
MA32705B1 (fr) | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation | |
TNSN06188A1 (fr) | Derives de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de recepteurs de chimiokines | |
CA2449729A1 (fr) | Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments | |
TNSN06073A1 (en) | Derives de benzimidazolone a activite agoniste des recepteurs 5-ht4 | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
MA27428A1 (fr) | Derives de pyrimidine et leur utilisation en tant que modulateurs cb2 | |
MXPA04001940A (es) | Tratamiento para desordenes del sistema nervioso central. | |
MA30037B1 (fr) | Compositions et procedes destines au traitement des troubles du snc | |
MA27692A1 (fr) | Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments | |
TNSN99031A1 (fr) | Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
RS50578B (sr) | Supstituisani 2-aminotetralini za preventivni tretman parkinsonove bolesti | |
MA29723B1 (fr) | Composes | |
MA27412A1 (fr) | Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases | |
MY124786A (en) | Bis-arylsulfones | |
ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren |